Welcome to Nofinity

This session analyzes 21 charts including Bitcoin, crypto, AI stocks, and macro assets, focusing on volatility, support/resistance levels, and the impact of NVIDIA's earnings.

Volatility and Market Overview

• Volatility spikes every 6-8 weeks; currently in a quiet phase. Large spikes often indicate black/gray swan events, like the April 2024 tariff tantrum which offered great opportunities.
• NASDAQ (QQQ): Downtrend is flattening; a turnaround is possible depending on NVIDIA's results.
• S&P 500: Unstoppable due to money printing, though it has volatile moments.

Bitcoin (BTC)

• Monster week: The 'Top and Bottom Indicator' exited the blue zone (buying area) since April. The buying opportunity in the bear market is closing.
• Key Level: Price is struggling at $78,847 (Level 7 of the Lila model). Two models show confluence here (Level 4 on ATR).
• Mean Reversion: Very high spike, last seen after the US election in November 2024. A price drop often follows but not immediately. No sell signals on ATR.
• 12-Month Target: The Lila model predicts $111,000–112,000, which is optimistic but uncertain.

Altcoins

• Solana (SOL): Broke above $100 but fell back. Strong resistance at $112 (Level 2). On-chain activity is booming (70% of all blockchain transactions).
• Ethereum (ETH): Resistance at $2,481 (Level 3), a historical level (sell signals since April 2025). However, a buy signal at $2,469 and an upward trend.
• Total Crypto Market Cap: Clean jump, adding $600–650 billion in 5 days – massive wealth creation.

Stocks

• MicroStrategy (MSTR): Outperformed Bitcoin (+40% vs +25%). STRC is recovering from $72 to $97.2.
• NVIDIA (NVDA): Historically sells off after earnings. Results: revenue and earnings beat, data center strong. Expectation: price below $21, but a buy zone at $19 (kill box). A miss would have crashed the entire AI market.
• Marvell (MRVL): 'Marvelous Marvell' – from $70–80 to $240, further potential from Google warrants (support at $210–212).
• AMD: Bullish, analyst target $650 in 6-12 months (currently $480). Good entry points near $460.
• Palantir (PLTR): Surprisingly strong despite high short interest from Michael Burry (tripled shorts). TA shows overbought but price isn't falling. Long-term strong, but a pullback is expected.
• Tesla (TSLA): Perplexing – despite the upcoming Cybercab event (Sept 3) and Optimus progress, market shows little interest.
• Copper: 'No-brainer macro trade of the decade', keeps hitting all-time highs, target $10 in 2-3 years.

Others

• SpaceX: Trend turned after IPO (currently $139). High volatility expected.
• Pair Trading: Tesla/SpaceX pair works well (40% more SpaceX shares). Echoar/SpaceX not recommended.
• Palantir vs. Shorts: Remains strong despite high short interest (Michael Burry tripled shorts). Fundamentals (EPS growth) are compelling.

Conclusion

• Patience Then Greed: The video's title reflects the strategy. Many assets (Solana, AMD, Copper) offer long-term opportunities. Short-term caution is advised, especially after the NVIDIA run.
• Upcoming: Next week, Hansy Nelson will discuss AI (Google, Palantir, Tesla, SpaceX).

Summary follows...

The 2 Amino Acids That Restore Muscle Strength & Burn 78% More Fat

This summary analyzes a study on GlyNAC (Glycine + N-Acetylcysteine) and its effects on mitochondrial health, muscle strength, and fat metabolism in older adults.

• Mitochondrial Dysfunction: Aging muscle cells lose the ability to efficiently burn fatty acids.
• Glutathione Deficiency: Intracellular glutathione, the cell's master antioxidant, is reduced by up to 70% in older adults.
• Root Cause: Two rate-limiting building blocks – glycine and cysteine – are equally depleted with age.

• Mechanism: The cell needs both amino acids to produce glutathione. Glycine and NAC provide the missing components.
• Study Design: 24 overweight older adults (61-80 years) received 100 mg/kg glycine + 100 mg/kg NAC daily (approximately 9 g per amino acid for a 90 kg person) for 16 weeks.

• Glutathione Increase: +225% in red blood cells, +164% in muscle biopsies – reaching levels of young adults.
• Fat Oxidation: +78% increase.
• Muscle Strength:
  • Gait Speed: +0.21 m/s (matching young adult levels)
  • Grip Strength: +4.4 kg (dominant hand)
  • Chair Rise Test: -6.8 seconds (better leg power)
• No Muscle Gain: Lean mass remained unchanged. Strength gains resulted from improved mitochondrial efficiency.

• Anti-Inflammatory: Interleukin-6 decreased by 78%, TNF-alpha by 54%, protective interleukin-10 nearly doubled.
• Insulin Resistance: HOMA-IR decreased by 64%.
• Oxidative Stress: DNA damage markers dropped by 73%.
• Blood Pressure: Systolic decreased from 132 to 124 mmHg.

• High Dosage: The study used very high doses (18 g of amino acids daily). Lower doses have not been tested.
• No Sustained Effect: After stopping GlyNAC, glutathione levels and strength gains returned to baseline.
• Lifespan Extension: The often-cited 24% lifespan increase comes from a mouse study, not human data.

GlyNAC addresses a core cause of age-related strength and energy loss: glutathione deficiency. The results are promising but require medical supervision, especially at high doses and regarding potential drug interactions.

• A 49-year-old sets the ambitious goal to dunk a basketball – a symbol of youthful athleticism and vitality.
• He trains with a professional coach who works with NBA players and has been at it for nearly 3 months.

• Instead of abstract metrics like VO2max (which he previously pushed to elite 18-year-old levels), he now focuses on a visible, relatable target.
• A dunk resonates with people: „The best biomarker I could ever achieve.“

• Phase 1 (first 2 months): Build a strong physiological base – especially tendon health and stiffness (tendons adapt in 8–12 weeks, muscles in 3–4).
• Phase 2 (from month 3): Add strength (for force production) and later speed (rate of force development).
• Current vertical jump measurement: 23.9 inches (approx. 60.7 cm) – baseline.

• After 3 months he feels clear gains and more trust in his body.
• The coach estimates an 80–85% success probability – aided by lean physique, good nutrition and sleep.
• Key: precise execution of drills (e.g., knees over toes in squats, bouncy movements).

„It‘s not about stopping the negative, it‘s about doing the positive.“ – The journey to a dunk is a statement against age limits.

• Clarity Act Fails: The first major US crypto regulation bill died in the Senate (49:50, 10 votes short). Coinbase stock fell 8%, Circle ~10%. Bitcoin ignored it.
• Fed Rate Hike: The US Federal Reserve raised rates by 25 basis points (first since 2023). The 10-year Treasury yield spiked above 5%, the Bank of Japan hiked to a 31-year high. Bitcoin still rose.
• AI Sector Weakens: Anthropic's CEO warned about runaway AI progress. Sam Altman and Elon Musk agreed. The semiconductor index dropped over 5%; Nvidia, ASML, SoftBank all fell. Crypto remained unfazed.

• 84% of liquidations were shorts ($843M of $1B total).
• In a single hour, over $300M was liquidated, 97% of it shorts.
• Between 126,000 and 135,000 accounts were closed.
• One wallet lost 375 BTC (~$32.5M) in four sequential liquidations over 14 hours.
• Mechanics: Forced buying from short liquidations pushes price higher → triggers next layer of shorts → cascade.

• Clarity Act irrelevant for markets: A failed bill changes nothing about Bitcoin's functionality (blocks, trades, custody). Crypto grew to over $1 trillion without US regulation.
• Institutions keep buying:
  • Strategy (MicroStrategy) bought 950 BTC for $75M right in the worst news week.
  • US spot Bitcoin ETFs lost $450M on voting day, but regained $433M just three sessions later.
  • Morgan Stanley's Bitcoin ETF logged 20 consecutive days of net inflows.

• China ban 2021: >50% of global hashrate went offline → Bitcoin rose from $29K to new ATH in 4 months.
• FTX collapse Nov 2022: Low of $15,400 – the absolute bottom.
• US banking crisis March 2023: Three banks failed, USDC depegged → Bitcoin rallied 40%.
• Inverse: Coinbase IPO April 2021 (peak) and ETF approval January 2024 (price fell from 49K to 38K) – good news marked tops.

Bitcoin is not a market that only rises on good news. The current rally through three parallel shocks shows: A strong holder base and institutional demand drive price independently of politics and macro. Future headlines may be just as grim – but crypto has proven itself through years of uncertainty and hostility. The question: Higher from here, or a bull trap?

Kaspi.kz (NASDAQ: KSPI) is a super app from Kazakhstan that covers nearly the entire financial and daily life of the country. The stock offers a dividend yield of almost 9 %, a P/E ratio of about 7, and growth of around 17 % – for the analyst, it's hard to find much wrong.

• Monopoly position: 85 % of payment processing and 70 % market share in consumer commerce in Kazakhstan.
• Government integration: Deep cooperation with the government and central bank – considered “too big to fail.” After a short-seller report (Culper Research), regulators immediately defended the company.
• Super app: Used for healthcare, government services, and banking – practically the entire population depends on it.
• Monopoly with political backing: This only works in Kazakhstan, but there it is a legal money-printing machine.

• Acquisition of Turkish e-commerce leader Hepsiburada for $1.1 billion.
• Acquisition of a banking license (Rabobank license) and planned capital injection of $300 million.
• Expansion of a “Buy Now, Pay Later” business and integration of fintech solutions into the Turkish platform.
• If Turkish profitability even approaches Kazakh levels, this could become a major winner.

• Net income is growing, stable net margin of around 27 %.
• E-commerce growth and payment business are strong thanks to the monopoly position.
• Non-performing loans (NPL): About 6–7 % and slightly rising – worth watching, but cushioned by high interest rates (15 % central bank rate).
• Balance sheet: $15 billion in customer loans, $17 billion in customer deposits – typical bank risks, but with fintech margins.

• Kazakhstan risk: Political connections, corruption allegations, possible rumors about bank stability.
• Dependence on the state: If political support changes, the business model would be in danger.
• Currency risk: Tenge fluctuations, but growth remains strong when measured in dollars.
• Bank risk: As a financial company, always vulnerable to loss of confidence and potential bank runs.

• P/E of 8 with 15 % growth and an 8–9 % dividend yield provide a margin of safety.
• Tencent as an investor and the “Silk Belt and Road” connection to China are additional strategic pluses.
• Founders own 66 % of the capital – without them the construct would not work, which creates resilience.
• The analyst is considering adding the stock to his diversified portfolio, although he considers the environment risky. “Hard to find much wrong” – but it remains an engaged emerging-market investment.

The Bitcoin price has surged from $68,000 to $87,000 in just two weeks, approaching the predicted October target of $90,000. Exchange-traded funds (ETFs) are seeing strong inflows, and long-term holders have significantly reduced their selling, which is considered a bullish signal. The price has broken through the 50-week moving average, suggesting further gains, while institutional investors are increasingly using MicroStrategy to gain exposure to Bitcoin. The purchasing power of the US dollar continues to decline due to inflation.